A Denmark-based vaccine producer announced that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include indications for monkeypox and related orthopoxvirus infections and disease in adults 18 years of age and older determined to be at high risk for exposure.
IMVAMUNE is currently approved in Canada under the Extraordinary Use New Drugs Pathway.
Read More
